{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T18:29:55Z","timestamp":1791138595617,"version":"4.1.0"},"reference-count":29,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2001,12,24]],"date-time":"2001-12-24T00:00:00Z","timestamp":1009152000000},"content-version":"vor","delay-in-days":510,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2000,8]]},"abstract":"<jats:p>Hypersensitivity reactions are relevant adverse effects of asparaginase therapy. Therefore, children treated with native <jats:italic>Escherichia coli<\/jats:italic> asparaginase in induction therapy of acute lymphoblastic leukaemia (ALL) or non\u2010Hodgkin's lymphoma (NHL) were switched to the pegylated enzyme for reinduction under drug monitoring. Seventy children, including four patients with allergic reactions during induction, were given one dose of Oncaspar<jats:sup>TM<\/jats:sup> 1000\u2003U\/m<jats:sup>2<\/jats:sup> intravenously. Activity was determined every third or fourth day until it dropped below the limit of quantification. In current reinduction protocols [ALL\/NHL\u2010Berlin\u2013Frankfurt\u2013M\u00fcnster (BFM) 95 trials], four doses of 10\u2003000\u2003U\/m<jats:sup>2<\/jats:sup><jats:italic>E. coli<\/jats:italic> asparaginase deplete asparagine for about 2\u20133\u2003weeks, therefore activities of \u2265\u200a100\u2003U\/l up to day 14 and \u2265\u200a50\u2003U\/l up to day 21 were targeted. In 66 patients without an allergic reaction during induction, the mean activity was 606\u2003\u00b1\u2003313\u2003U\/l, 232\u2003\u00b1\u2003211\u2003U\/l and 44\u2003\u00b1\u200350\u2003U\/l after 1, 2 and 3\u2003weeks respectively. In 44\/66 patients, activity was \u2265\u200a100\u2003U\/l after 14\u2003d. A rapid decline in activity was seen in the remaining 22 patients, including 8\/22 patients who showed no activity after 1\u2003week. Toxicity was low and comparable to the native enzymes but, in contrast to about 30% of hypersensitivity reactions with conventional reinduction therapy, no allergic reaction was seen. Substituting 4\u2003\u00d7\u200310\u2003000\u2003U\/m<jats:sup>2<\/jats:sup> asparaginase medac for one dose of 1000\u2003U\/m<jats:sup>2<\/jats:sup> Oncaspar<jats:sup>TM<\/jats:sup> was safe and well tolerated. Comparable pharmacokinetic treatment intensity was achieved in about two\u2010thirds of patients.<\/jats:p>","DOI":"10.1046\/j.1365-2141.2000.02187.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T06:27:06Z","timestamp":1047364026000},"page":"379-384","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":106,"title":["Pegylated asparaginase (Oncaspar<sup>TM<\/sup>) in children with ALL: drug monitoring in reinduction according to the ALL\/NHL\u2010BFM 95 protocols"],"prefix":"10.1111","volume":"110","author":[{"given":"Hans\u2010Joachim","family":"M\u00fcller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lutz","family":"L\u00f6ning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Horn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Schwabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Gunkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Schrappe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volker","family":"Von Sch\u00fctz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcnter","family":"Henze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o","family":"Casimiro da Palma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Ritter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o Paulo Vieira","family":"Pinheiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Winkelhorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Boos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2001,12,24]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.9.1780"},{"key":"e_1_2_6_3_1","first-page":"556","article-title":"Relative toxicity of E. colil\u2010asparaginase (ASP) and PEG asparaginase (PEG) in newly diagnosed childhood acute lymphoblastic leukemia (ALL)","volume":"21","author":"Asselin B.","year":"1993","journal-title":"Medical and Pediatric Oncology"},{"key":"e_1_2_6_4_1","volume-title":"NONMEM User's Guides.","author":"Beal S.L.","year":"1992"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/0003-9861(69)90041-1"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF03259347"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/0959-8049(96)00131-1"},{"key":"e_1_2_6_8_1","first-page":"111","article-title":"l\u2010Asparaginase: discovery and development as a tumor\u2010inhibitory agent","volume":"65","author":"Broome J.D.","year":"1981","journal-title":"Cancer Treatment Reports"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1006\/excr.1995.1317"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/mpo.2950220614"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197610)38:4<1843::AID-CNCR2820380463>3.0.CO;2-J"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/mpo.2950180612"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1203\/00006450-198519040-00017"},{"issue":"1","key":"e_1_2_6_14_1","first-page":"669a","article-title":"Toxicity and pharmacokinetics of PEG\u2010asparaginase (PEG\u2010asp) in newly diagnosed adult acute lymphoblastic leukemia (ALL): CALGB 9511","volume":"88","author":"Frankel S.R.","year":"1996","journal-title":"Blood"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/mpo.2950030410"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428199309149129"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197601)37:1<220::AID-CNCR2820370132>3.0.CO;2-W"},{"key":"e_1_2_6_18_1","first-page":"304","article-title":"Antibodies to asparaginase alter pharmacokinetics and decrease enzyme activity in patients on asparaginase therapy","volume":"34","author":"Kurtzberg J.","year":"1993","journal-title":"Proceedings of the American Association for Cancer Research"},{"key":"e_1_2_6_19_1","first-page":"183","article-title":"Amino acid levels following \n\t\t\t\t\t\tl\u2010asparagine amidohydrolase (EC 3.5.1.1.) therapy","volume":"29","author":"Miller H.K.","year":"1969","journal-title":"Cancer Research"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/0378-1119(86)90163-0"},{"key":"e_1_2_6_21_1","first-page":"127","article-title":"Influence of two different Escherichia coli asparaginase preparations on fibrinolytic proteins in childhood ALL","volume":"81","author":"Nowak\u2010G\u00f6ttl U.","year":"1996","journal-title":"Haematologica"},{"key":"e_1_2_6_22_1","first-page":"2297","article-title":"Biochemical and pharmacological studies with asparaginase in man","volume":"30","author":"Ohnuma T.","year":"1970","journal-title":"Cancer Research"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(70)80023-3"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2008-1046608"},{"key":"e_1_2_6_25_1","first-page":"4554","article-title":"l\u2010Asparaginase pharmacokinetics and asparagine levels in cerebrospinal fluid of rhesus monkeys and humans","volume":"41","author":"Riccardi R.","year":"1981","journal-title":"Cancer Research"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2008-1046607"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00685615"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1999.01192.x"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-60377-8_81"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/9780470122846.ch3"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2141.2000.02187.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2141.2000.02187.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2141.2000.02187.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,29]],"date-time":"2023-10-29T16:28:51Z","timestamp":1698596931000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2141.2000.02187.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,8]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2000,8]]}},"alternative-id":["10.1046\/j.1365-2141.2000.02187.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2141.2000.02187.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,8]]},"assertion":[{"value":"2001-12-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}